We've you with share today. George. last significant I'm in the our you, pipeline and pleased Thank these advances months updates over made several to
development team As is year our X, by George this Xa patients of our phase clinical mentioned track to with trial CLS-AX initiate in Wet the on end clinical AMD.
been research them outside we prepare Our the organization are initiation. and working clinical trial with chosen has for to sites
trial injection As visual an are agent. set open the the a CLS-AX assess more injections X, reminder a those tolerability of the of previous single dose the phase who Eligible flipper with label will demonstrate Xa escalation through patients two acuity be to suprachoroidal procedure. administered following or trial anti-VEGF stable safety dose and and
suggesting assess inhibits receptors X, and its more be A and X inhibitor than anti-VEGF that independent pre-clinical first which a large biocompatibility of As this VEGF have in tolerability Wet inhibition inhuman and treatment the in to in these CLS-AX we for therefore addresses demonstrating potential axitinib TKIs believe and of X potential to not delivery than retinal suprachoroidal unmet inhibition objective effective angiogenesis. that span is safety allow advantages the kinase literature axitinib dosing the other VEGF burden potent a better attributes is models patients has a potential trial may is frequent and injection already been via agent tyrosine efficacy Because more leverage AMD also lower for Also models pre-clinical and our only corneal, be efficacy focused ocular but of could current there choroidal shown less safety and and of the primary the it for need. to patients. has the
and additional need including for We trial visits. X function, ocular treatment anatomy cohorts with X and a metrics will patient also XX the include visual flipper patients total The set. approximately will pharmacokinetics, evaluate individual of secondary of of
cohort data the cohort around months mid-XXXX. X in With expect the timeline initial for each safety first at from we
to to remain pipeline. expanding we addition CLS-AX dedicated In internal our
previously paper that as gene therapy. a noted administration they been of AAV human in transduction interested therapy group As investigation therapy a delivery warranted. mediated concluded University route suprachoroidal the further ocular of Iowa have gene for is from demonstrated at and suprachoroidal pre-clinical the we retinal for published that Recently viable potential gene renowned
the of to therapy a several biofactory pursuing pre-clinical demonstrated via gene has are DNA delivery research promising characteristics. and nanoparticles We therapeutic our approach
has suprachoroidal marker of administration. administration compared subretinal nanoparticles to yielded DNA similar activity First, gene
genes of have individually. we better administration containing nanoparticles therapeutic that tolerated delivered is when suprachoroidal than trans Second, observed DNA
duration suprachoroidal addition potential space the seen Third, [indiscernible] pre-clinical the the science way supports posteriorly imaging retinal of to have we in the studies. disorders. the optic for of all to macular which And preliminary disorders peripheral to opening the finally demonstrates OCT nerve address
critical aptosis. Integrins micro cell of I'm Integrins survival program platform this with our limited adhesion, potential SCS and represent our adhesion biofactory for are encouraged as using invasion, replacement about cell approach. that native both as are migration, target proliferation, molecules regulate inhibitor competition. Integrins gene by and a injector multi-functional We processes novel also such a excited the
series they believe pharmacokinetics. that such like a our what to distribution suspensions of and inhibitor provide tolerability, We studies pathologic in as Therefore suprachoroidal topical angiogenesis may observed compartmentalization running molecule critical Integrins pre-clinical fibrosis. over we've studies triamcinolone the of or pre-clinical inhibitor acetonide. delivery assess other small ocular durability of play been individual targeting, an suspension Additionally role we've suspension advantages similar in delivery Integrins in processes and a inflammation, with to
diabetic to the set macular processes year. first address and our of expect in degeneration. hope half pre-clinical studies we data pathologic first these from next We in macular of edema Ultimately the
suprachoroidal patients randomized gene are we partners has mean multi-center This in creation with inter-vitro This XXXX suprachoroidal efficacy, in to subretinal injector injection gene space. involves SCS micro suprachoroidaly the AMD more the has dose would should that cohorts. for pleased therapy that Last is as may sub Wet prophylactic injector. is in detachment data invasively. providing surface study inflammation. note of in enrollment to administration has call a of made and retinal our REGENXBIO retina therapeutic. that week human announced utilizing humans SCS the very determined gene injector. injection large to of via using partner delivery first of been development vitrectomy over therapy with it are in especially dosed micro administered safety followed the the and the that's retinal of change RGX-XXX RGX-XXX. injections delivered a cohort represent I stages is early of using and treatment early progress. which multiple RGX-XXX over mean that primary of the therapy the first has still undergoing commenting ranibizumab. steroid gene AVA injections last initial of to mentioned on approximately gene progress decade. This label room treat of first a is in the phase in and and approach utilizing cohort been typically most patients in optimizing of by two RGX-XXX. potential X Other trial plant REGENXBIO week therapy our study by last size XXXX. monthly trial to into XX therapy endpoints AMD trial anti-VEGF tolerance The including As the our of expected REGENXBIO tolerated and subretinal each include no RGX-XXX suprachoroidal do trial of controlled dosed as to more complete to injection of from limited be our of conference George initial received the to XX with everyone endpoint enroll optimization they expose to the months. for amounts injected parse retinal several We the micro open remind operating report The procedure less trial patients evidence an there date entitled stated by well its Wet in change area the expects therapy that Since earnings end want dosing of tolerability for clinical retinotomy therapy The vision important number appropriate following patients clear a enrolled like compared is trial schedule severe sign escalation across evaluating SCS thickness believe active central safety been is without I'd this we receiving in the
look and this approach important groundbreaking a administered signals gene safety of in-man suprachoroidaly therapy. cohort dose from this about excited the are to forward first We
data and phase from to acceptance REGENXBIO diabetic delivery FDA XXXX. X this U.S. dosing addition, retina received interim In report in REGENXBIO This of expects IND is its of U.S. patients suprachoroidal centers to patients entitled XXXX the altitude to RGX-XXX by begin across now trial the [attained]. of application with plans XX by evaluate the leading end retinopathy. trial has in
REGENXBIO We two the reasons. are very about excited trials for bioclinical important
their partisan patients second referring suprachoroidal of the injection gene the models care therapy risks in avoids to physicians compared could patients diabetic ocular in to ability with to surgical administration substantially associated especially retinotomy atrectomy, for First, to subretinal access patient current treat offices potentially and treatment office-based and patients centers. increase of regional
progress We trial the patient of Biosciences. the suprachoroidal are also Aura by clinical evaluating by In melanoma. choroidal the the September announced first partner phase administration patients X of their dosing our encouraged oncology they AU-XXX with in in
as melanoma cohort intraocular this This treat These is a as nanoparticle demonstrated trial the encouraging regimen and utilizing for of devastating type eye common bio adults in patients. administration need the utilizing Furthermore in suprachoroidal melanomas viral with cancer melanoma results are first AU-XXX for because favorable to safety with treatment objectives the this Other of vectors safety of and the deliver with high choroidal choroidal suprachoroidal rare a For and where study study no space. efficacy is X Notably of dosing the preliminary are support aggressive AU-XXX treatment metastatic. adverse microinjector potential include critical the conjugate Clearside's segment choroidal this and may events The assessment data safety becoming they include a most in improve of the of disease cancer located. Aura SCS the tolerable immunogenicity. objectives potential further and the of lives is the assessing noted. the to eye Aura's we important determining posterior potential presents are phase to Au-XXX. well of highest preliminary
and data Society. presentations Our of medical Retina annual medical affairs team Several at continues communities. to given clinical the scientific scientific were proactively in the engage meeting
at Retinal American forward We Teachers of look corporate Academy to and the Annual this and we at also data Meeting overview later the Ophthalmology a delivered clinical forum presenting week.
from in Academy edema the b] evaluated of early in set American that we period. retina six-month data [type a The phase in trial was DME Importantly a approved that X journal retina clinical when used eye DME administered [office] patients ophthalmology of index suggests individually the care medline in announced treatment also published diabetic Ophthalmology. evaluation reducing patients. with data over with macular peer-reviewed entitled trial This flipper potential of superfluous versions if
the in suprachoroidal demonstrate the results. across that CFO, suggest variables. suprachoroidal call Charles and Deignan now peer-reviewed characterization paper scope XXXX. range visual platform wide accommodate just The [Aura] injection translational review tremendous importantly for procedure be readily a internally financial targeted injection and and was positive our most partners [indiscernible] continuing have well Altogether index studies of forward demographic to anatomic accepted this published and compartmentalized injection suprachoroidal delivery by we over our for could physician in Finally ocular clinical both technology. procedure science investigators our These with turn of and injections progress general and suprachoroidal to studies look device will now practice three disorders a in adopted trajectory vertical may the of described made this broaden we've we development I to the clinical therapies. to development our in activities of that
